Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
105
resultados
Última actualización
20/08/2025 [07:25:00]
Resumen de: CN120484133A
本发明提供了一种基于猪圆环病毒2型(PCV2)纳米抗体与沙门氏菌鞭毛蛋白的重组融合蛋白及其制备方法与应用。本发明将PCV2衣壳蛋白(Cap)特异性纳米抗体基因与沙门氏菌鞭毛蛋白基因融合，使用大肠杆菌原核表达系统表达制备了Nbcap‑flagellin重组融合蛋白。该重组融合蛋白能够利用Cap蛋白特异性纳米抗体的靶向结合能力，实现鞭毛蛋白佐剂与抗原蛋白的动态偶联，形成佐剂用量可调控的抗原‑佐剂复合物；在充分发挥鞭毛蛋白作为免疫佐剂作用的同时，突破传统鞭毛蛋白与抗原蛋白融合表达导致的固定佐剂‑抗原配比限制，提升了疫苗设计的灵活性，避免了细菌鞭毛蛋白过量可能引发的炎性反应，为开发高效、安全且广谱的PCV2亚单位疫苗提供了新的技术路径。
Resumen de: WO2025170108A1
The present invention relates to identifying and engineering a tail spike protein gene from a genome of bacteriophage SFP10 infected with a Salmonella strain, purifying and producing a recombinant protein using mSFP10TSP, which is a recombinant protein formulation for detecting Salmonella enterica, EGFP-mSFP10TSP fused with a green fluorescent protein, and SiBD-mSFP10TSP fused with an SiBD, and thereby specifically detecting the Salmonella strain.
Resumen de: WO2025170306A1
The present invention relates to an antibacterial composition comprising, as an active ingredient, a plantaricin peptide derived from a Lactiplantibacillus plantarum KM2 strain, wherein the plantaricin peptide derived from the strain and a plantaricin peptide combination were found to have antimicrobial activity against at least one selected from the group consisting of Flavobacterium sp, Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus, and acromobacter xylosoxidans (Alcaligenese xylosoxidans), Salmonella enterica, <i />and Vibrio parahaemolyticus, and the plantaricin peptide and the plantaricin peptide combination were found to have antibacterial activity and a cell wall lysis effect against the Flavobacterium sp. strain, and accordingly, the plantaricin peptide derived from the Lactiplantibacillus plantarum KM2 strain and the plantaricin peptide combination are provided as antimicrobial agents.
Resumen de: WO2025165867A1
Provided herein are compositions comprising in vivo succinate-producting microorganisms, e.g., Bacteroides and Prevotella species (preferably Bacteroides thetaiotaomicron (e.g., VPI 5482), Bacteroides vulgatus (e.g., NCTC 11154, Prevotella copri (e.g., DSM 18205)), Parabacteroides (e.g., Parabacteroides distasonis), and Bacilli (e.g. Lactobacillus animalis), and methods of use thereof in treating or reducing risk of developing an intestinal infection, optionally an infection with Campylobacter, Salmonella, E. coli, Shigella, Listeria monocytogenes, Vibrio, Enteropathogenic E. coli, Klebsiella, or Clostridioides difficile, or promoting expansion of colonic tuft cells, in a subject.
Resumen de: MX2025007790A
Methods and antimicrobial compositions are provided for surface cleaning. The antimicrobial compositions which include very low concentrations of an organic acid and one or more anionic surfactants can, unexpectedly, provide effective and broad spectrum antimicrobial activity within two minutes of contact with a surface and in some instances within one minute of contact time. Contacting the antimicrobial compositions with a surface can result in greater than or equal to about 4.0 log kill or 5.0 log kill for one or more of <i>Staphylococcus aureus</i>, <i>Pseudomonas aeruginosa</i>, and <i>Salmonella enterica </i>on the surface in two minutes or less. The compositions can have antimicrobial activity against at least one gram-positive bacterium, gram-negative bacterium, virus, and fungus in two minutes or less of contacting the composition with a surface.
Resumen de: CN119907682A
Provided herein are vaccine compositions comprising a Salmonella antigen conjugated to a capsid wherein the capsid comprises a wild-type or native sequence. Also provided herein are vaccine compositions comprising a Salmonella antigen conjugated to a capsid wherein the capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the prevention or treatment of Salmonella infection (salmonellosis), in the treatment and prevention of gastroenteritis, typhoid and/or paratyphoid; and the method can effectively aim at various salmonella strains.
Resumen de: CN119923470A
The present invention relates to a modified live attenuated Salmonella strain comprising at least one chromosomal integrated synthetic polynucleotide sequence inserted in a predetermined pseudogenomic position, said sequence comprising at least one defined recombination site for introducing a heterologous polynucleotide sequence encoding a polypeptide, wherein the chromosome integration synthetic polynucleotide sequence is located within at least one genomic site, the genomic site being defined by any one of SEQ ID NO: 1-30 or a sequence having at least 70% identity with any one of SEQ ID NO: 1-30. The invention also relates to vaccine compositions comprising the modified strains and various uses and methods thereof.
Resumen de: GB2637451A
Disclosed are a lactobacillus farciminis SR2 and a use thereof. The present lactobacillus farciminis SR2 shows good tolerance under an acidic condition of pH = 3.0, has strong adaptability in 45 C° high-temperature and high salt (10% NaCl) environment, inhibits the growth of harmful bacteria such as escherichia coli, staphylococcus aureus, and salmonella, has high productivity of ferulic acid esterase, can significantly lower the pH level of rice straw silage feed, significantly increase the content of lactic acid, significantly reduce the content of ammonia nitrogen, significantly increase the content of dry matter and WSC, significantly reduce the content of NDF, ADF and cellulose, improve the fermentation quality of the rice straw silage feed, and the method can be widely applied to the field of rice straw fermentation feed preparation.
Resumen de: CN120366177A
本发明提供一种四基因敲除减毒鼠伤寒沙门氏菌及其构建方法和应用，所提供的一种四基因敲除减毒鼠伤寒沙门氏菌，是敲除了鼠伤寒沙门氏菌的relA、Asd、manA和sifA基因。本发明构建了四种毒力因子缺失的鼠伤寒沙门氏菌的减毒菌株ΔrelA‑ΔAsd‑ΔmanA‑ΔsifA SM14028，可在体外稳定传代。并经安全性评价试验检测，该菌株毒力无毒力，安全性极高。为了进一步评价ΔrelA‑ΔAsd‑ΔmanA‑ΔsifA SM14028是否能够抵抗亲本株的攻击，进行了免疫效力评价，结果显示，ΔrelA‑ΔAsd‑ΔmanA‑ΔsifA SM14028能够提供有效的免疫保护。因此，本发明的ΔrelA‑ΔAsd‑ΔmanA‑ΔsifA SM14028可作为一种有效的活疫苗或者活载体疫苗，为动物疫病的防控奠定基础。
Resumen de: CN119630803A
The present invention relates to an extracellular vesicle containing an antigen protein or a gene encoding the protein, and a use thereof, and more specifically, to an extracellular vesicle containing an antigen protein derived from a virus, a microorganism or a cancer cell or a gene encoding the protein, or a vaccine composition for preventing or treating viral infections, microbial infections or cancers comprising the same. The extracellular vesicle or the vaccine composition comprising the same according to the present invention is a platform applicable to various diseases, has excellent antigen-specific immune response induction effect and stability, and is expected to be effectively used in the field of vaccine development. The vaccines are useful for the prevention or treatment of various diseases including viral infections, microbial infections or cancers.
Resumen de: WO2025152055A1
Provided is a method for testing the in-vitro bactericidal function of a typhoid vaccine immune serum, comprising: testing the in-vitro bactericidal function of a typhoid vaccine immune serum against Salmonella typhi bacteria by means of an opsonophagocytic killing assay, wherein when the phagocytic killing step of the opsonophagocytic killing assay is completed, the Salmonella typhi bacteria having undergone the phagocytic killing step are cultured at the pH of 7.5-9.5. The opsonophagocytic killing assay is applied to Gram-negative Salmonella Typhi bacteria for the first time, and the in-vitro bactericidal levels of typhoid vaccine immune serums are effectively and accurately evaluated.
Resumen de: AU2023338191A1
The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live
Resumen de: WO2024050627A1
Purified antigens are usually weakly immunogenic and require the addition of immunostimulatory agents and/or delivery systems to generate robust antigen-specific responses. The present application relates to self-assembling polypeptides that may be conjugated to immunogens and have the ability to self-assemble into immunogen-displaying nanofilaments that activate the humoral and cellular immune responses. The self-assembling polypeptide comprises an amino acid sequence having at least 60% identity with the sequence of the R4 and R5 domains from a Curli-specific gene A (CsgA) protein. The present application also relates to nucleic acids encoding the self-assembling polypeptide/immunogen conjugates, to compositions and vaccines comprising the self-assembling polypeptide/immunogen conjugates or nucleic acids, as well as to methods for inducing an immune response against an immunogen and/or for preventing and/or treating a microbial infection, cancer or any pathological conditions in which vaccination may be useful such as autoimmune diseases and allergies, in a subject.
Resumen de: CN120290433A
本发明公开了一种基于鞭毛蛋白和LPS减毒的鼠伤寒沙门氏菌EN‑VNP菌株及其制备方法和应用，具体涉及生物技术领域。该菌株是通过在沙门氏菌VNP 20009菌株基础上，依次敲除或沉默鞭毛蛋白基因fliC、fljB、磷酸乙醇胺转移酶基因eptA、4‑氨基‑4‑脱氧‑L‑阿拉伯糖转移酶基因arnT、磷酸转移酶yeiU，并敲入或过表达磷酸转移酶基因lpxE形成的。本发明的鼠伤寒沙门氏菌EN‑VNP菌株具有较高的安全性，减毒后的菌株不含有鞭毛蛋白且LPS的脂质A分子仅保留一个磷酸基团，提高了菌株的安全性，使其更适合作为疫苗和药物递送载体。
Resumen de: US2025222089A1
Provided are compositions and methods that include a K. pneumoniae yidR protein or an antigenic segment of the protein, and homologous of the protein, and antigenic segments of the homologs. The compositions can be provided as vaccine formulations for use with humans and non-human animals, including but not limited to dairy cows. The compositions and methods are useful for prophylaxis and/or therapy of conditions associated with Gram negative bacteria that include K. pneumonia, E. coli, and other pathogenic Gram negative bacteria. The conditions include such bacterial infections generally, and include specifically mastitis and metritis. The compositions and methods can also improve fertility and milk production. Administration of the compositions can improve the likelihood of a first service conception.
Resumen de: US2025222101A1
A composition for treatment of African Swine Fever in swine includes avian-sourced antibodies specific for an African Swine Fever Virus isolate. These antibodies are produced by avian animals immunized against the African Swine Fever Virus isolate and mixed with a protective/reactive matrix obtained from, isolated from, or derived from, non-hyperimmune colostrum.
Resumen de: US2025224367A1
Disclosed herein are biosensors, and, more particularly, biosensors using carbon nanotubes, an electronic reader for use with the biosensors, and systems and methods employing them. The biosensors employ preserved biologics on the carbon nanotubes which results in shelf-stable, robust biosensors.
Resumen de: CN120267813A
本发明涉疫苗领域，具体而言涉及一种CpG佐剂与抗原定点共价结合方法。本发明方法采用分步偶联策略，使用HUH蛋白与相匹配的特异性识别ssDNA序列偶联系统、异肽键分子粘合剂系统以及融合表达系统等实现CpG佐剂与抗原以1:1的摩尔比定点偶联，并且所得到的偶联物具有提高疫苗的免疫刺激的效果。
Resumen de: CN120249162A
本发明提供一种减毒鼠伤寒沙门氏菌及其应用，所提供的减毒鼠伤寒沙门氏菌，是通过敲除relA基因、manA基因和sifA基因制备的。本发明所提提供的三基因沙门氏菌减毒株，通过口服免疫将抗原呈递给宿主细胞，从而诱导机体产生免疫应答。沙门氏菌作为活载体的作用机理为携带细菌抗原通过肠道上皮后，通过肠道粘膜将其转运至免疫细胞，触发了宿主的免疫应答。本发明构建的减毒株经安全性检测发现，该减毒株安全性高，可作为载体，运载其他致病抗原或药物到达作用部位，进而起到载体作用。
Resumen de: CN119744171A
The present disclosure relates to novel therapeutic regimens for the treatment of autoimmune and other inflammatory diseases using BTK (Bruton's Tyrosine Kinase) inhibitors. In particular, the present disclosure relates to treatments that combine BTK inhibitor treatments with vaccination to avoid, reduce the risk of staining, or ameliorate infection. In addition, the present disclosure relates to vaccination in the presence of a BTK inhibitor.
Resumen de: WO2025143588A1
The present invention relates to a spheroplast protein y (Spy)-exogenous protein-secreting Salmonella strain, which possesses a Spy protein-coding gene and has the rpoE gene deleted. The recombinant Salmonella strain according to the present invention, while exhibiting attenuated virulence due to the Spy protein, can maintain structural stability when fused with exogenous proteins such as pathogenic viruses, therapeutic proteins, or antigenic epitopes, through the structure and chaperone functions of the Spy protein. Therefore, the present invention can serve as a live attenuated vaccine. Furthermore, the present invention can be used as a protein delivery vehicle, a drug delivery vehicle, and in antigen-antibody reaction-based techniques for applications in other areas of biotechnology.
Resumen de: CN120230694A
本发明提供一种同时缺失invF基因、spaL基因、sipC基因、prgH基因中的两种或两种以上的多基因缺失的鼠伤寒沙门菌。本发明还公开了上述多基因缺失的鼠伤寒沙门菌的构建方法，及其在制备鼠伤寒沙门菌减毒活疫苗中的应用。本发明提供的四基因同时缺失的鼠伤寒沙门菌缺失株较野生型鼠伤寒沙门菌的毒力显著下降，在宿主体内的定殖时间显著缩短，接种后小鼠无不良反应，对强毒力鼠伤寒沙门菌提供良好的保护作用，可有效清除强毒力菌株的感染；应用于鼠伤寒沙门菌减毒活疫苗具有良好的免疫原性，可对小鼠提供坚实的免疫保护效果，具有广泛的应用前景。
Resumen de: CN120210397A
The invention provides a novel salmonella molecular detection method based on an EXPAR-CRISPR/Cas12a detection system, the method specifically amplifies a yfiR gene of salmonella through an EXPAR isothermal technology, and uses a CRISPR/Cas12a system for cutting and detection, and has the advantages of rapidness, sensitivity, strong specificity and the like.
Resumen de: CN120204382A
The invention discloses a novel Kdo-MPLA adjuvant, and relates to the technical field of synthetic biology, the adjuvant is formed by connecting monophosphate lipid A (MPLA) and Kdo sugar through an alpha-glucosidic bond, MPLA is of a structure formed by modifying salmonella lipid A through 4 '-site monophosphorylation, and the Kdo sugar is endowed with amphipathy, so that the Kdo sugar is self-assembled into liposome nanoparticles in an aqueous solution; the rfaC and eptA genes are double knocked out through a gene editing salmonella attenuated strain, wherein the rfaC knockout blocks the synthesis of LPS core polysaccharide, and lipid A-Kdo connection is reserved; knocking out eptA to obtain a monophosphorylated lipid A; after the engineering bacteria are fermented, high-purity Kdo-MPLA is obtained by adopting a phenol-chloroform-petroleum ether extraction method, the process is simplified, and the product is uniform; the adjuvant can activate a TLR4 signal channel and induce Th1 type immune response, the levels of inflammatory factors IL-6 and IL-1beta are remarkably lower than those of natural LPS, and the adjuvant is suitable for a mixed preparation of vaccine antigens such as HPV and malaria; the method overcomes the defects of hydrolysis uncontrollability and high chemical synthesis cost of the traditional MPLA chemical extraction process.
Nº publicación: CN120210147A 27/06/2025
Solicitante:
ZHEJIANG UNIV OF TECHNOLOGY
\u6D59\u6C5F\u5DE5\u4E1A\u5927\u5B66
Resumen de: CN120210147A
The invention discloses a high-activity transaminase mutant with L-alanine as an amino donor and application of the high-activity transaminase mutant in synthesis of L-glufosinate-ammonium, and provides a novel high-activity transaminase mutant from salmonella, L-alanine is used as the amino donor to asymmetrically synthesize L-glufosinate-ammonium, so that the use amount of L-alanine is reduced, the cost is reduced, and the yield of L-glufosinate-ammonium is increased. And the space-time conversion rate is improved, and the industrial production cost is reduced.
BOPI
Sede Electrónica
